FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries

HILLERØD, Denmark – FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP1 facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator. The commercial manufacturing falls under the agreement between Lilly and the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator, to supply potential Lilly therapeutic antibodies for the prevention and treatment of COVID-19. The Therapeutics Accelerator is an initiative launched by the Gates Foundation, Wellcome, and Mastercard to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments.

Earlier this year, FUJIFILM Diosynth Biotechnologies announced that it had reserved manufacturing capacity for the COVID-19 Therapeutics Accelerator, at its large scale biologics production facility in Hillerød. Commercial manufacturing of the Lilly antibody therapy is expected to commence in April 2021. 

“To help bring the devastating impact of the pandemic to an end, FUJIFILM Diosynth Biotechnologies is honored to support the COVID-19 Therapeutics Accelerator and its mission to bring equitable access to novel treatments,” said Martin Meeson, chief executive officer at FUJIFILM Diosynth Biotechnologies. “With the rapid development of COVID-19 vaccines and therapeutics, FUJIFILM Diosynth Biotechnologies will continue to leverage our technical leadership, world-class facilities and commercial manufacturing flexibility, to help accelerate production to meet patient needs around the world.”

FUJIFILM Diosynth Biotechnologies’ Hillerød cGMP facility is equipped with 6 x 20,000L bioreactors for the manufacture of cell culture derived biologics for clinical and commercial use and recently announced an investment of $928M USD to double this capacity and add drug product filling capabilities. This agreement accounts for part of the production capacity in this facility, which also produces other biologic products.

“I am very proud of the hardworking men and women at our Hillerød facility that will play a crucial role in manufacturing COVID-19 antibodies for patients in low- and middle-income countries,” said Lars Petersen, chief operating officer, FUJIFILM Diosynth Biotechnologies, Denmark. “This important initiative from the COVID-19 Therapeutics Accelerator and Lilly will ensure that these therapies will be accessible to those in need in regions with limited resources.”


 Good Manufacturing Practice


About Fujifilm 
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.  For more information, go to: www.fujifilmdiosynth.com


FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com



All product and company names herein may be trademarks of their registered owners.


Media Contact:
FUJIFILM Corporation Corporate Communications Division
TEL : +81 3-6271-2000
FUJIFILM Holdings America Corporation
TEL : +1 914-789-8523

Other Contact:
FUJIFILM Corporation Bio CDMO Division
TEL : +81 3-6271-3025